Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy

Cancer Research

Volumn 73, Issue 21, 2013, Pages 6393-6400

  Todaro, Matilde ^a   Turdo, Alice ^a   Bartucci, Monica ^b   Iovino, Flora ^a   Dattilo, Rosanna ^b   Biffoni, Marco ^c   Stassi, Giorgio ^a   Federici, Giulia ^b   De Maria, Ruggero ^d   Zeuner, Ann ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ERYTHROPOIETIN RECEPTOR; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN BCL XL; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CANCER TISSUE; CELL ISOLATION; CELL PROLIFERATION; CELL PROTECTION; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT;

ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; ERYTHROPOIETIN; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84887148630     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0248     Document Type: Article

References (20)

1. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin a maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23: 2597-605.
2. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009; 101: 1633-41.
3. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299: 914-24.
4. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373: 1532-42.
5. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27: 2838-47.
6. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71.
7. Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. In: U.S. Food and Drug Administration ODAC, editor; 2007.
8. Risk evaluation and mitigation strategy BL 103234 EPOGEN/PROCRIT (EPOETIN ALFA). In: Administration FaD, editor; 2010.
9. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010;18: 423-35.
10. Hedley BD, Chu JE, Ormond DG, Beausoleil MS, Boasie A, Allan AL, et al. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin Cancer Res 2011;17: 6151-62.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100: 3983-8.
12. Badve S, Nakshatri H. Breast-cancer stem cells-beyond semantics. Lancet Oncol 2012;13:e43-8.
13. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 2012;122: 2066-78.
14. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100: 672-9.
15. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, et al. Markers of tumorinitiating cells predict chemoresistance in breast cancer. PLoS ONE 2010;5:e15630.
16. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1: 555-67.
17. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1: 389-402.
18. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65: 5506-11.
19. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers CD44, CD24, and ALDH1: expression distributionwithin intrinsic molecular subtype. JClin Pathol 2011;64: 937-46.
20. Migliaccio AR, Jiang Y, Migliaccio G, Nicolis S, Crotta S, Ronchi A, et al. Transcriptional and posttranscriptional regulation of the expression of the erythropoietin receptor gene in human erythropoietin-responsive cell lines. Blood 1993;82: 3760-9.